Research Topics
| Jean L GremSummaryAffiliation: University of Nebraska Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancerGregory D Leonard
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Naval Medical Center, Bethesda, MD 20889 5105, USA
BMC Cancer 5:116. 2005..Oxaliplatin, an agent used in first-line therapy for metastatic colorectal cancer, causes acute and chronic neurotoxicity. This study was performed to carefully assess the incidence, type and duration of oxaliplatin neurotoxicity...
Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancerJean L Grem
Department of Internal Medicine, Section of Oncology Hematology, and the Eppley Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA
Semin Oncol 32:120-7. 2005....- Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumorsJean L Grem
Nebraska Medical Center, Omaha, NE 68198 7680, USA
J Clin Oncol 23:1885-93. 2005..To determine the clinical toxicities of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) given as a 1-hour infusion daily for 5 days every 3 weeks... 
Fatigue and other variables during adjuvant chemotherapy for colon and rectal cancerAnn M Berger
University of Nebraska Medical Center in Omaha, USA
Oncol Nurs Forum 37:E359-69. 2010....
Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabineKazumi Uchida
University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE 68198, USA
BMC Cancer 8:386. 2008..Over-expression of ERCC1 correlates with insensitivity to oxaliplatin (OX) therapy, while high thymidine phosphorylase (TP) levels predict for increased sensitivity to capecitabine (Xel)...- Mature results of adjuvant colon cancer trials from the fluorouracil-only eraJean L Grem
J Natl Cancer Inst 96:727-9. 2004 - A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowelAbdel Salam Attia Ismail
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute-Navy, National Naval Medical Center, Bethesda, MD 20889-5105, USA
Oncol Rep 13:1145-52. 2005..6 and 100.0 min, respectively. A 1-h infusion of 5-FU is well tolerated; individual dose escalation of 5-FU allows each patient to receive the maximum tolerable dose... - A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumorsMaurice A Wright
Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
Clin Cancer Res 11:4144-50. 2005..CONCLUSIONS: Doses (mg/m(2)) of CPT-11 140/24 hours, leucovorin 500/0.5 hours and 5-FU 3,120/48 hours were well tolerated... - Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal functionChris H Takimoto
Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78245 3217, USA
Clin Cancer Res 13:4832-9. 2007..To characterize the pharmacokinetics and pharmacodynamics of oxaliplatin in cancer patients with impaired renal function... - Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working GroupRamesh K Ramanathan
Translational Genomics Research Institute, 13208 E Shea Blvd, Ste 100, Scottsdale, AZ 85259, USA
J Clin Oncol 26:563-9. 2008..To develop dosing guidelines and to evaluate the pharmacokinetics of imatinib in patients with liver dysfunction (LD)... - Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working GroupJoseph Gibbons
Case Comprehensive Cancer Center, Ireland Cancer Center at University Hospitals of Case Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH, USA
J Clin Oncol 26:570-6. 2008.... - Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working groupChris H Takimoto
Medicine Branch at Navy, National Naval Medical Center, National Cancer Institute, Bethesda, MD, USA
Semin Oncol 30:20-5. 2003..These data suggest that dose reductions of single-agent oxaliplatin are not necessary in patients with CrCLs >20 mL/min... - Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyChris H Takimoto
University of Texas Health Science Center at San Antonio, Cancer Therapy and Research Center, 7979 Wurzbach Rd, Room Z415, San Antonio, TX 78229, USA
J Clin Oncol 21:2664-72. 2003..This study was undertaken to determine the toxicities, pharmacokinetics, and maximum tolerated doses of oxaliplatin in patients with renal impairment and to develop formal guidelines for oxaliplatin dosing in this patient population... - A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusionJorge Leguizamo
National Cancer Institute-Navy Medical Oncology, Cancer Therapeutics Branch, Center for Cancer Research, National Naval Medical Center, Bethesda, Maryland, USA
Cancer Chemother Pharmacol 52:333-8. 2003..13 mg/m2 per day). The Cpss of 9-AC lactone at this dose exceeded the 10 nM threshold level for preclinical activity... - Hypersensitivity and idiosyncratic reactions to oxaliplatinRebecca R Thomas
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, NCI-Navy Medical Oncology, National Naval Medical Center, Bethesda, Maryland 20889-5105, USA
Cancer 97:2301-7. 2003.... - Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly scheduleXiao-Du Guo
National Cancer Institute-Navy Medical Oncology, Cancer Therapeutics Branch, Center for Cancer Research, National Naval Medical Center, Bethesda, MD 20889-5105, USA
Cancer Chemother Pharmacol 52:79-85. 2003.... - A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patientsJean L Grem
National Cancer Institute Navy Hematology Oncology, National Naval Medical Center, Bethesda, Maryland 20889, USA
Clin Cancer Res 8:2149-56. 2002..We assessed the clinical toxicities and pharmacologic effects of PZA given as a 24-h i.v. infusion weekly for 3 of 4 weeks... - A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorinJean L Grem
National Cancer Institute Navy Medical Oncology, National Naval Medical Center, Bethesda, MD 20889, USA
Cancer Chemother Pharmacol 52:487-96. 2003..Since preclinical studies have shown more than additive cytotoxicity and DNA damage with the combination of gemcitabine and 5-fluoro-2'-deoxyuridine (FUDR), we studied this combination in a phase I trial... - Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cellsJean L Grem
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute Navy Medical Oncology, National Naval Medical Center, Bethesda, MD 20889 5105, USA
Anticancer Drugs 13:259-70. 2002..The clinical evaluation of UCN-01 combined with 5-fluoropyrimidines may be of interest... - Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibitionBruce Keith
National Cancer Institute-Navy Medical Oncology, Cancer Therapeutics Branch, Center for Cancer Research, National Naval Medical Center, Bethesda, Maryland 20889-5105, USA
Clin Cancer Res 8:1045-50. 2002..4 versus 287.6 pmol/min/mg). CONCLUSIONS: When eniluracil is given with 5-FU/LV, DPD inhibition appears to be influenced by schedule, and the time to recovery is much longer than has been observed with eniluracil given alone... - Epirubicin, Cisplatin, and protracted venous-infusion Fluorouracil in advanced esophagogastric cancerGregory D Leonard
J Clin Oncol 20:4124-5; author reply 4125-6. 2002 - Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channelsRichard G Webster
Neurosciences Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
Br J Pharmacol 146:1027-39. 2005..The similarity between beta-pompilidotoxin and oxaliplatin suggests that alteration of voltage-gated Na(+) channel kinetics is likely to underlie the acute neurotoxic actions of oxaliplatin... - Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasmaYan Xu
Gastrointestinal Malignancies Section, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, 20889-5105, Bethesda, MD, USA
J Chromatogr B Analyt Technol Biomed Life Sci 783:273-85. 2003..0500-25.0 microgram/ml for the metabolites, 5'-deoxy-5-fluorocytidine and 5'-deoxy-5-fluorouridine, respectively. This method has been used to analyze plasma samples from patients receiving capecitabine in combination with oxaliplatin... - Screening for dihydropyrimidine dehydrogenase deficiencyJean L Grem
Clin Cancer Res 11:5067-8. 2005 - Severe disabling sensory-motor polyneuropathy during oxaliplatin-based chemotherapyGregory D Leonard
National Cancer Institute-Navy Medical Oncology, Bethesda, MD, USA
Anticancer Drugs 15:733-5. 2004..Heightened clinical suspicion for possible oxaliplatin-induced motor neuropathies may be warranted... - Cardiac toxicity associated with capecitabine therapyM Wasif Saif
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NCI-Navy Medical Oncology, National Naval Medical Center, Bethesda 20889-5105, USA
Acta Oncol 42:342-4. 2003 - Acute oxaliplatin-induced peripheral nerve hyperexcitabilityRichard H Wilson
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
J Clin Oncol 20:1767-74. 2002..Efforts to identify a successful neuroprotectant strategy would have a major impact on improving patient quality of life and the ability to deliver full doses of oxaliplatin...